Monitoring of minimal residual disease in children with acute promyelocytic leukemia by RT-PCR detecting PML/RAR alpha chimeric gene: A retrospectivestudy of clinical feasibility

We studied retrospectively the clinical feasibility of minimal residual dis ease (MRD) monitoring by reverse transcription-polymerase chain reaction (R T-PCR) detecting the PML/retinoic acid receptor alpha (RAR alpha) chimeric gene in children with acute promyelocytic leukemia (APL). MRD monitoring of APL was performed with standard and nested RT-PCR for PML/RAR alpha gene, the sensitivity of which was 1 leukemic cell in 10(3)-10(4) and 1 in 10(4)- 10(5) cells, respectively. Patients were nine children with APL (average ag e: 8.3 year; average period of follow-up: 69.2 months) who, after achieving remission with all-trans retinoic acid (ATRA), received treatment; either with multidrug chemotherapy or with a combination of chemotherapy and ATRA. Out of six patients treated with multidrug-combined chemotherapy, two pati ents exhibited PCR positivity after six months of post-remission therapy, w hich shifted from the detectable range of the nested PCR to that of the sta ndard PCR. These two patients subsequently relapsed and, together with two of the other patients receiving multidrug-combined chemotherapy, underwent allogeneic bone marrow transplantation. No MRD was detected in these patien ts after transplantation. In the remaining three patients who underwent cyc lic treatment with alternative chemotherapy and ATRA, two showed positive R T-PCR at the nested or standard level, respectively, after six months of co mbined therapy, and one of them relapsed. Overall, three of four patients w ith MRD detected in post-remission period ultimately relapsed, while all of five patients without detectable MRD had a good prognosis. These findings suggest that impending relapse may be predicted by the detection of precedi ng PCR positivity with an increasing quantity of the PML/RAR alpha mRNA tha t appears beyond six months of post-remission chemotherapy, with or without combined ATRA therapy.-APL; MRD monitoring; PML/RAR alpha; RT-PCR (C) 2001 Tohoku University Medical Press.